Search This Blog

Friday, May 29, 2020

Phio Pharma up on positive data from Intasyl programs: ASCO

Phio Pharmaceuticals (NASDAQ:PHIO) is up 14% premarket after announcing positive data from in vivo studies that show strong antitumoral efficacy with several of its INTASYL pipeline programs, including PH-762, PH-894 and PH-804.
These results show that intratumoral delivery of INTASYL compounds inhibited tumor growth by overcoming the immunosuppressive tumor microenvironment (TME) as shown by changes in T cell composition and activation.
These data were presented during the ASCO 2020 Virtual Scientific Program.
PH-762, PH-894 and PH-804 are INTASYL compounds designed to silence the expression of PD-1, BRD4 and TIGIT, respectively, which are proteins linked to reduced immune cell function in cancer patients.
https://seekingalpha.com/news/3578616-phio-pharmaplus-14-on-positive-data-from-intasyl-programs

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.